Skip to main content

The Pivotal Role of Mitsugumin 53 in Cardiovascular Diseases

Cardiovascular Toxicology volume 21, pages 2–11 (2021)Cite this article

Abstract

The MG53 (also known as TRIM72) is a conserved, muscle-specific tripartite motif family protein that is abundantly expressed in cardiac or skeletal muscle and present in circulation. Recently, the MG53 had been hypothesized to serve a dual role in the heart: involving in repairing cell membranes that protect myocardial function while acting as an E3 ligase to trigger insulin resistance and cardiovascular complications. This review discusses the roles of MG53 in cardiac physiological function with emphasis on MG53 protective function in the heart and its negative impact on the myocardium due to the continuous elevation of MG53. Besides, this work reviewed the significance of MG53 as a potential therapeutic in human cardiovascular diseases. Despite the expression of MG53 being rare in the human, thus exogenous MG53 can potentially be a new treatment for human cardiovascular diseases. Notably, the specific mechanism of MG53 in cardiovascular diseases remains elusive.

This is a preview of subscription content, access via your institution.

Access options

Buy single article

Instant access to the full article PDF.

43,34 €

Price includes VAT (Finland)
Tax calculation will be finalised during checkout.

References

  1. Nisole, S., Stoye, J. P., & Saïb, A. (2005). TRIM family proteins: retroviral restriction and antiviral defence. Nature Reviews Microbiology, 3(10), 799–808.

    CAS  PubMed  Article  Google Scholar 

  2. Parky, E. Y., Kwony, O. B., Jeong, B. C., Yi, J. S., Lee, C. S., Ko, Y. G., et al. (2010). Crystal structure of PRY-SPRY domain of human TRIM72. Proteins, 78(3), 790–795.

    Google Scholar 

  3. Liu, W., Wang, G., Zhang, C., Ding, W., Cheng, W., Luo, Y., et al. (2019). MG53, a novel regulator of KChIP2 and Ito, f, plays a critical role in electrophysiological remodeling in cardiac hypertrophy. Circulation, 139(18), 2142–2156.

    CAS  Article  PubMed  Google Scholar 

  4. Hwang, M., Ko, J. K., Weisleder, N., Takeshima, H., & Ma, J. (2011). Redox-dependent oligomerization through a leucine zipper motif is essential for MG53-mediated cell membrane repair. American Journal of Physiology - Cell Physiology, 301(1), C106–114.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  5. Kim, S., Seo, J., Ko, Y. G., Huh, Y. D., & Park, H. (2012). Lipid-binding properties of TRIM72. BMB Reports, 45(1), 26–31.

    CAS  PubMed  Article  Google Scholar 

  6. Tan, T., Ko, Y. G., & Ma, J. (2016). Dual function of MG53 in membrane repair and insulin signaling. BMB Reports, 49(8), 414–423.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  7. Lee, C., Yi, J. S., Jung, S. Y., Kim, B. W., Lee, N. R., Choo, H. J., et al. (2010). TRIM72 negatively regulates myogenesis via targeting insulin receptor substrate-1. Cell Death and Differentiation, 17(8), 1254–1265.

    CAS  PubMed  Article  Google Scholar 

  8. Duann, P., Li, H., Lin, P., Tan, T., Wang, Z., Chen, K., et al. (2015). MG53-mediated cell membrane repair protects against acute kidney injury. Science Translational Medicine, 7(279), 279ra236.

    Article  CAS  Google Scholar 

  9. Jia, Y., Chen, K., Lin, P., Lieber, G., Nishi, M., Yan, R., et al. (2014). Treatment of acute lung injury by targeting MG53-mediated cell membrane repair. Nature Communications, 5, 4387.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  10. Cai, C., Takeshima, H., Masumiya, H., Weisleder, N., Pan, Z., Nishi, M., et al. (2009). MG53 regulates membrane budding and exocytosis in muscle cells. Journal of Biological Chemistry, 284(5), 3314–3322.

    CAS  Article  Google Scholar 

  11. Cai, C., Takeshima, H., Weisleder, N., Ko, J. K., Komazaki, S., Sunada, Y., et al. (2009). Membrane repair defects in muscular dystrophy are linked to altered interaction between MG53, Caveolin-3, and Dysferlin. Journal of Biological Chemistry, 284(23), 15894–15902.

    CAS  Article  Google Scholar 

  12. Cai, C., Masumiya, H., Weisleder, N., Matsuda, N., Nishi, M., Hwang, M., et al. (2009). MG53 nucleates assembly of cell membrane repair machinery. Nature Cell Biology, 11(1), 56–64.

    CAS  PubMed  Article  Google Scholar 

  13. Wang, X., Xie, W., Zhang, Y., Lin, P., Han, L., Han, P., et al. (2010). Cardioprotection of ischemia/reperfusion injury by cholesterol-dependent MG53-mediated membrane repair. Circulation Research, 107(1), 76–83.

    CAS  PubMed  Article  Google Scholar 

  14. Jung, S. Y., & Ko, Y. G. (2010). TRIM72, a novel negative feedback regulator of myogenesis, is transcriptionally activated by the synergism of MyoD (or myogenin) and MEF2. Biochemical and Biophysical Research Communications, 396(2), 238–245.

    CAS  PubMed  Article  Google Scholar 

  15. Yi, J. S., Park, J. S., Ham, Y. M., Nguyen, N., Lee, N. R., Hong, J., et al. (2013). MG53-induced IRS-1 ubiquitination negatively regulates skeletal myogenesis and insulin signalling. Nature Communications, 4, 2354.

    PubMed  PubMed Central  Article  Google Scholar 

  16. Weisleder, N., Takizawa, N., Lin, P., Wang, X., Cao, C., Zhang, Y., et al. (2012). Recombinant MG53 protein modulates therapeutic cell membrane repair in treatment of muscular dystrophy. Science Translational Medicine, 4(139), 139ra185.

    Article  CAS  Google Scholar 

  17. Yao, Y., Zhang, B., Zhu, H., Li, H., Han, Y., Chen, K., et al. (2016). MG53 permeates through blood–brain barrier to protect ischemic brain injury. Oncotarget, 7(16), 22474–22485.

    PubMed  PubMed Central  Article  Google Scholar 

  18. Corona, B. T., Garg, K., Roe, J. L., Zhu, H., Park, K. H., Ma, J., et al. (2014). Effect of recombinant human MG53 protein on tourniquet-induced ischemia-reperfusion injury in rat muscle. Muscle and Nerve, 49(6), 919–921.

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  19. Yao, W., Li, H., Han, X., Chen, C., Zhang, Y., Tai, W. L., et al. (2017). MG53 anchored by dysferlin to cell membrane reduces hepatocyte apoptosis which induced by ischaemia/reperfusion injury in vivo and in vitro. Journal of Cellular and Molecular Medicine, 21(10), 2503–2513.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  20. Timmis, A., Townsend, N., Gale, C., Grobbee, R., Maniadakis, N., Flather, M., et al. (2018). European society of cardiology: Cardiovascular disease statistics 2017. European Heart Journal, 39(7), 508–579.

    PubMed  Article  Google Scholar 

  21. Camp, G. V. (2014). Cardiovascular disease prevention. Acta Clinica Belgica, 69(6), 407–411.

    PubMed  Article  Google Scholar 

  22. Benjamin, E. J., Muntner, P., Alonso, A., Bittencourt, M. S., Callaway, C. W., Carson, A. P., et al. (2019). Heart disease and stroke statistics—2019 update: A report from the American Heart Association. Circulation, 139(10), e56–e528.

    PubMed  PubMed Central  Article  Google Scholar 

  23. Nguyen, N., Yi, J. S., Park, H., Lee, J. S., & Ko, Y. G. (2014). Mitsugumin 53 (MG53) ligase ubiquitinates focal adhesion kinase during skeletal myogenesis. Journal of Biological Chemistry, 289(6), 3209–3216.

    CAS  Article  Google Scholar 

  24. Cai, C., Lin, P., Zhu, H., Ko, J. K., Hwang, M., Tan, T., et al. (2015). Zinc binding to MG53 protein facilitates repair of injury to cell membranes. Journal of Biological Chemistry, 290(22), 13830–13839.

    CAS  Article  Google Scholar 

  25. Masumiya, H., Asaumi, Y., Nishi, M., Minamisawa, S., Adachi-Akahane, S., Yoshida, M., et al. (2009). Mitsugumin 53-mediated maintenance of K+ currents in cardiac myocytes. Channels (Austin), 3(1), 6–11.

    CAS  Article  Google Scholar 

  26. Cao, C. M., Zhang, Y., Weisleder, N., Ferrante, C., Wang, X., Lv, F., et al. (2010). MG53 constitutes a primary determinant of cardiac ischemic preconditioning. Circulation, 121(23), 2565–2574.

    CAS  PubMed  Article  Google Scholar 

  27. Wu, H. K., Zhang, Y., Cao, C.-M., Hu, X., Fang, M., Yao, Y., et al. (2019). Glucose-sensitive myokinecardiokine MG53 regulates systemic insulin response and metabolic homeostasis. Circulation, 139(7), 901–914.

    CAS  PubMed  Article  Google Scholar 

  28. Chen, X., Su, J., Feng, J., Cheng, L., Li, Q., Qiu, C., et al. (2019). TRIM72 contributes to cardiac fibrosis via regulating STAT3/Notch-1 signaling. Journal of Cellular Physiology, 234(10), 17749–17756.

    CAS  PubMed  Article  Google Scholar 

  29. Steinhardt, R. A., Bi, G., & Alderton, J. M. (1994). Cell membrane resealing by a vesicular mechanism similar to neurotransmitter release. Science, 263(5145), 390–393.

    CAS  PubMed  Article  Google Scholar 

  30. McNeil, P. L., & Kirchhausen, T. (2005). An emergency response team for membrane repair. Nature Reviews Molecular Cell Biology, 6(6), 499–505.

    CAS  PubMed  Article  Google Scholar 

  31. Miyake, K., & McNeil, P. L. (2003). Mechanical injury and repair of cells. Critical Care Medicine, 31(Supplement), S496–501.

    PubMed  Article  Google Scholar 

  32. Liu, J., Zhu, H., Zheng, Y., Xu, Z., Li, L., Tan, T., et al. (2015). Cardioprotection of recombinant human MG53 protein in a porcine model of ischemia and reperfusion injury. Journal of Molecular and Cellular Cardiology, 80, 10–19.

    CAS  PubMed  Article  Google Scholar 

  33. Zhang, C., Chen, B., Wang, Y., Guo, A., Tang, Y., Khataei, T., et al. (2017). MG53 is dispensable for T-tubule maturation but critical for maintaining T-tubule integrity following cardiac stress. Journal of Molecular and Cellular Cardiology, 112, 123–130.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  34. He, B., Tang, R. H., Weisleder, N., Xiao, B., Yuan, Z., Cai, C., et al. (2012). Enhancing muscle membrane repair by gene delivery of MG53 ameliorates muscular dystrophy and heart failure in δ-Sarcoglycan-deficient hamsters. Molecular Therapy, 20(4), 727–735.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  35. McNeil, P. (2009). Membrane repair redux: redox of MG53. Nature Cell Biology, 11(1), 7–9.

    CAS  PubMed  Article  Google Scholar 

  36. Mastorci, F., Sabatino, L., Vassalle, C., & Pingitore, A. (2020). Cardioprotection and thyroid hormones in the clinical setting of heart failure. Frontiers in Endocrinology, 10, 927.

    PubMed  PubMed Central  Article  Google Scholar 

  37. Mathers, C. D., & Loncar, D. (2006). Projections of global mortality and burden of disease from 2002 to 2030. PLoS Medicine, 3(11), e442.

    PubMed  PubMed Central  Article  Google Scholar 

  38. Garcia-Dorado, D., Ruiz-Meana, M., & Piper, H. M. (2009). Lethal reperfusion injury in acute myocardial infarction: Facts and unresolved issues. Cardiovascular Research, 83(2), 165–168.

    CAS  PubMed  Article  Google Scholar 

  39. Yellon, D. M., & Hausenloy, D. J. (2007). Myocardial reperfusion injury. New England Journal of Medicine, 357(11), 1121–1135.

    CAS  Article  Google Scholar 

  40. Janero, D. R., Hreniuk, D., & Sharif, H. M. (1991). Hydrogen peroxide-induced oxidative stress to the mammalian heart-muscle cell (cardiomyocyte): Lethal peroxidative membrane injury. Journal of Cellular Physiology, 149(3), 347–364.

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  41. Zhang, Y., Wu, H.-K., Lv, F.-X., & Xiao, R.-P. (2016). MG53 is a double-edged sword for human diseases. Sheng Li Xue Bao, 68(4), 505–516.

    PubMed  PubMed Central  Google Scholar 

  42. Lacerda, L., Somers, S., Opie, L. H., & Lecour, S. (2009). Ischaemic postconditioning protects against reperfusion injury via the SAFE pathway. Cardiovascular Research, 84(2), 201–208.

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  43. Zhou, X., Mingxian, C., Wang, S., Yu, L., & Jiang, H. (2015). MG53 protein: A promising novel therapeutic target for myocardial ischemia reperfusion injury. International Journal of Cardiology, 199, 424–425.

    PubMed  Article  PubMed Central  Google Scholar 

  44. Yellon, D. M., & Downey, J. M. (2003). Preconditioning the myocardium: From cellular physiology to clinical cardiology. Physiological Reviews, 83(4), 1113–1151.

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  45. Tsutsumi, Y. M., Horikawa, Y. T., Jennings, M. M., Kidd, M. W., Niesman, I. R., Yokoyama, U., et al. (2008). Cardiac-specific overexpression of caveolin-3 induces endogenous cardiac protection by mimicking ischemic preconditioning. Circulation, 118(19), 1979–1988.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  46. Murry, C. E., Jennings, R. B., & Reimer, K. A. (1986). Preconditioning with ischemia: A delay of lethal cell injury in isChemic myocardium. Circulation, 74(5), 1124–1136.

    CAS  PubMed  Article  Google Scholar 

  47. Kohr, M. J., Evangelista, A. M., Ferlito, M., Steenbergen, C., & Murphy, E. (2014). S-nitrosylation of TRIM72 at cysteine 144 is critical for protection against oxidation-induced protein degradation and cell death. Journal of Molecular and Cellular Cardiology, 69, 67–74.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  48. Chan, C. Y. X. A., Wang, D., Cadeiras, M., Deng, M. C., & Ping, P. (2014). S-nitrosylation of TRIM72 mends the broken heart: A molecular modifier-mediated cardioprotection. Journal of Molecular and Cellular Cardiology, 72, 292–295.

    CAS  PubMed Central  Article  PubMed  Google Scholar 

  49. Kloner, R. A., & Rezkalla, S. H. (2006). Preconditioning, postconditioning and their application to clinical cardiology. Cardiovascular Research, 70(2), 297–307.

    CAS  PubMed  Article  Google Scholar 

  50. Tsang, A., Hausenloy, D. J., Mocanu, M. M., & Yellon, D. M. (2004). Postconditioning: A form of “modified reperfusion” protects the myocardium by activating the phosphatidylinositol 3-kinase-akt pathway. Circulation Research, 95(3), 230–232.

    CAS  PubMed  Article  Google Scholar 

  51. Zhang, Y., Lv, F., Jin, L., Peng, W., Song, R., Ma, J., et al. (2011). MG53 participates in ischaemic postconditioning through the RISK signalling pathway. Cardiovascular Research, 91(1), 108–115.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  52. Lemckert, F. A., Bournazos, A., Eckert, D. M., Kenzler, M., Hawkes, J. M., Butler, T. L., et al. (2016). Lack of MG53 in human heart precludes utility as a biomarker of myocardial injury or endogenous cardioprotective factor. Cardiovascular Research, 110(2), 178–187.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  53. Adesanya, T. M. A., Russell, M., Park, K. H., Zhou, X., Sermersheim, M. A., Gumpper, K., et al. (2019). MG53 protein protects aortic valve interstitial cells from membrane injury and fibrocalcific remodeling. Journal of the American Heart Association, 8(4), e009960.

    PubMed  PubMed Central  Article  Google Scholar 

  54. Iung, B., Baron, G., Butchart, E. G., Delahaye, F., Gohlke-Bärwolf, C., Levang, O. W., et al. (2003). A prospective survey of patients with valvular heart disease in Europe: The Euro Heart Survey on Valvular Heart Disease. European Heart Journal, 24(13), 1231–1243.

    PubMed  Article  Google Scholar 

  55. Maron, B. J. (2002). Hypertrophic cardiomyopathy: A systematic review. JAMA, 287(10), 1308–1320.

    PubMed  Article  Google Scholar 

  56. Ham, Y. M., & Mahoney, S. J. (2013). Compensation of the AKT signaling by ERK signaling in transgenic mice hearts overexpressing TRIM72. Experimental Cell Research, 319(10), 1451–1462.

    CAS  PubMed  Article  Google Scholar 

  57. Xu, L., Wang, H., Jiang, F., Sun, H., & Zhang, D. (2020). LncRNA AK045171 protects the heart from cardiac hypertrophy by regulating the SP1/MG53 signalling pathway. Aging, 12(4), 3126–3139.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  58. Song, R., Peng, W., Zhang, Y., Lv, F., Wu, H. K., Guo, J., et al. (2013). Central role of E3 ubiquitin ligase MG53 in insulin resistance and metabolic disorders. Nature, 494(7437), 375–379.

    CAS  PubMed  Article  Google Scholar 

  59. Liu, F., Song, R., Feng, Y., Guo, J., Chen, Y., Zhang, Y., et al. (2015). Upregulation of MG53 induces diabetic cardiomyopathy through transcriptional activation of peroxisome proliferation-activated receptor α. Circulation, 131(9), 795–804.

    CAS  PubMed  Article  Google Scholar 

  60. Wang, Q., Bian, Z., Jiang, Q., Wang, X., Zhou, X., Park, K. H., et al. (2020). MG53 does not manifest the development of diabetes in db/db mice. Diabetes, 69(5), 1052–1064.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  61. Bian, Z., Wang, Q., Zhou, X., Tan, T., Park, K. H., Kramer, H. F., et al. (2019). Sustained elevation of MG53 in the bloodstream increases tissue regenerative capacity without compromising metabolic function. Nature Communications, 10(1), 4659.

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  62. Harville, E. W., Srinivasan, S., Chen, W., & Berenson, G. S. (2012). Is the metabolic syndrome a “small baby” syndrome?: The Bogalusa Heart Study. Metabolic Syndrome and Related Disorders, 10(6), 413–421.

    PubMed  PubMed Central  Article  Google Scholar 

  63. Levy, J. R., Campbell, K. P., & Glass, D. J. (2013). MG53′s new identity. Skeletal Muscle, 3(1), 25–25.

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  64. Despres, J. P., Lemieux, I., Bergeron, J., Pibarot, P., Mathieu, P., Larose, E., et al. (2008). Abdominal obesity and the metabolic syndrome: Contribution to global cardiometabolic risk. Arteriosclerosis, Thrombosis, and Vascular Biology, 28(6), 1039–1049.

    CAS  PubMed  Article  Google Scholar 

  65. Stern, M. P., Williams, K., González-Villalpando, C., Hunt, K. J., & Haffner, S. M. (2004). Does the metabolic syndrome improve identification of individuals at risk of type 2 diabetes and/or cardiovascular disease? Diabetes Care, 27(11), 2676–2681.

    PubMed  Article  Google Scholar 

  66. McMillen, I. C., & Robinson, J. S. (2005). Developmental origins of the metabolic syndrome: Prediction, plasticity, and programming. Physiological Reviews, 85(2), 571–633.

    CAS  PubMed  Article  Google Scholar 

  67. Grundy, S. M. (2006). Metabolic syndrome: Connecting and reconciling cardiovascular and diabetes worlds. Journal of the American College of Cardiology, 47(6), 1093–1100.

    CAS  PubMed  Article  Google Scholar 

  68. Finck, B. N., Han, X., Courtois, M., Aimond, F., Nerbonne, J. M., Kovacs, A., et al. (2003). A critical role for PPARα-mediated lipotoxicity in the pathogenesis of diabetic cardiomyopathy: Modulation by dietary fat content. Proceedings of the National Academy of Sciences of the United States of America, 100(3), 1226–1231.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  69. Wang, Z. V., & Hill, J. A. (2015). Diabetic cardiomyopathy: Catabolism driving metabolism. Circulation, 131(9), 771–773.

    PubMed  PubMed Central  Article  Google Scholar 

  70. Ma, H., Liu, J., Bian, Z., Cui, Y., Zhou, X., Zhou, X., et al. (2015). Effect of metabolic syndrome on mitsugumin 53 expression and function. PLoS ONE, 10(5), e0124128.

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  71. Ho, C. Y., López, B., Lakdawala, N. K., Cirino, A. L., Jarolim, P., et al. (2010). Myocardial fibrosis as an early manifestation of hypertrophic cardiomyopathy. The New England Journal of Medicine, 363(6), 552–563.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  72. Wagner, J. U. G., & Dimmeler, S. (2020). Cellular cross-talks in the diseased and aging heart. Journal of Molecular and Cellular Cardiology, 138, 136–146.

    CAS  PubMed  Article  Google Scholar 

  73. Jellis, C., Martin, J., Narula, J., & Marwick, T. H. (2010). Assessment of nonischemic myocardial fibrosis. Journal of the American College of Cardiology, 56(2), 89–97.

    CAS  PubMed  Article  Google Scholar 

  74. Zhao, J., & Lei, H. (2016). Tripartite motif protein 72 regulates the proliferation and migration of rat cardiac fibroblasts via the transforming growth Factor-β signaling pathway. Cardiology, 134(3), 340–346.

    CAS  PubMed  Article  Google Scholar 

  75. Park, J. S., Lee, H., Choi, B. W., Ro, S., Lee, D., Na, J. E., et al. (2018). An MG53-IRS1-interaction disruptor ameliorates insulin resistance. Experimental & Molecular Medicine, 50(6), 1–12.

    Article  CAS  Google Scholar 

  76. Guan, F., Huang, T., Wang, X., Xing, Q., Gumpper, K., Li, P., et al. (2019). The TRIM protein Mitsugumin 53 enhances survival and therapeutic efficacy of stem cells in murine traumatic brain injury. Stem Cell Research & Therapy, 10(1), 352.

    CAS  Article  Google Scholar 

  77. Li, X., Jiang, M., Tan, T., Narasimhulu, C. A., Xiao, Y., Hao, H., et al. (2020). N-acetylcysteine prevents oxidized low-density lipoprotein-induced reduction of mg53 and enhances mg53 protective effect on bone marrow stem cells. Journal of Cellular and Molecular Medicine, 24(1), 886–898.

    CAS  PubMed  Article  Google Scholar 

  78. Zhang, Y., Wu, H. K., Lv, F., & Xiao, R. P. (2017). MG53: Biological function and potential as a therapeutic target. Molecular Pharmacology, 92(3), 211–218.

    CAS  PubMed  Article  Google Scholar 

Download references

Acknowledgements

The time and effort expended by volunteer student (Gu LX) subjects are greatly appreciated. This work was supported by the following grants: National Natural Science Foundation of China Grant Nos. 91749108, 31671424. The Seed Foundation of Innvation and Creation for Graduate Students in Northwestern Polytechnical University (Grant No. CX202065 to Jiang WH). The Science and Technology Research and Development Program of Shaanxi Province, China (Grant No. 2015KW-050, 2018SF-101). The Youth Innovation Team of Shaanxi Universities, China. Language Editorial Service: Freescience Information Technology Co. Ltd (Ningbo, China).

Author information

Affiliations

  1. Institute of Medical Research, Northweastern Polytechnical University, Xi’an, 710072, People’s Republic of China

    Wenhua Jiang & Heng Ma

  2. Department of Physiology and Pathophysiology, School of Basic Medicine, Fourth Military Medical University, Xi’an, 710032, People’s Republic of China

    Manling Liu

  3. Department of Cardiovascular Surgery, Xijing Hospital, Fourth Military Medical University, Xi’an, 710032, People’s Republic of China

    Chunhu Gu

Authors
  1. Wenhua Jiang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Manling Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Chunhu Gu
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Heng Ma
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to Chunhu Gu or Heng Ma.

Ethics declarations

Conflict of interest

The authors state no conflict of interest.

Ethical Approval

This manuscript is a review article and does not involve a research protocol requiring approval by the relevant institutional review board or ethics committee.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Handling Editor: Martin Štěrba.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Jiang, W., Liu, M., Gu, C. et al. The Pivotal Role of Mitsugumin 53 in Cardiovascular Diseases. Cardiovasc Toxicol 21, 2–11 (2021). https://doi.org/10.1007/s12012-020-09609-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12012-020-09609-y

Keywords

  • MG53
  • Cardiovascular diseases
  • Insulin resistance
  • Ischemic cardiomyopathy